Cargando…
Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression?
The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application Lurasidone (Latuda, Sunovion Pharmaceuticals), an atypical antipsychotic, for the treatment of schizophrenia in adolescents 13–17 years of age. Lurasidone was previously indicated in the U.S. for the treatme...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009006/ https://www.ncbi.nlm.nih.gov/pubmed/29962579 http://dx.doi.org/10.4103/IJPSYM.IJPSYM_374_17 |